Background: In December 2019, in Wuhan, China, coronavirus disease 2019 (COVID-19) was emerged due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It seems that children and neonates, similar to adult and elderly individuals, are at risk of SARS-CoV-2 infection. However, adequate data are not available about neonates infected with SARS-CoV-2. Methods: This study evaluated the presence of SARS-CoV-2 infection in neonates born to mothers or relatives with COVID-19. This cross-sectional study was performed on 25,044 consecutive Iranian participants in Tehran, Iran, from January 2020 to August 2020. Viral ribonucleic acid (RNA) was extracted from 500 µl of the oropharyngeal and nasopharyngeal specimens of the participants. The genomic RNA of SARS-CoV-2 was detected by real-time polymerase chain reaction (PCR) assay. Results: Out of all participants, 98 (0.40%) cases were neonates born to mothers or relatives with SARS-CoV-2 infection. Therefore, the current study was performed on these neonates. Out of 98 studied neonates, 6 (6.1%) cases had positive PCR results for SARS-CoV-2 infection. Moreover, among 98 studied neonates’ mothers, 25 (25.5%) cases had positive PCR results for SARS-CoV-2 infection. Conclusion: The findings of this study demonstrated that the rate of COVID-19 in neonates born to mothers or relatives with SARS-CoV-2 infection in the Iranian population is about 6.1%.

The treatment of HIV presents significant challenges due to the low solubility and bioavailability of antiretroviral drugs. These limitations impact the absorption of the drugs in the gastrointestinal tract, leading to reduced effectiveness. Patients often exhibit varying responses due to inconsistent levels of the drug in their bloodstream. Achieving desired plasma concentrations is challenging and often requires higher doses that increase the risk of side effects. Developing drugs with low solubility is a complex and costly process, slowing down overall drug development. Traditional formulation strategies have proven ineffective in addressing these issues, necessitating exploration of innovative techniques. Nanocrystallization has emerged as a transformative approach that enhances solubility and dissolution rates by reducing drug particles to the nanometer scale. This increased surface area improves drug solubility and bioavailability. Nanocrystallized drugs demonstrate a faster onset of action, higher drug load, and enhanced safety and efficiency, offering a potential solution to the challenges posed by the poor water solubility of many antiretroviral drugs. This article delves into nanocrystal formulations of HIV drugs and examines the effectiveness of commonly used stabilizers and surfactants in nanocrystal production. The aim is to determine whether the popularization of nanocrystallization could potentially overcome the prevalent issues of low solubility and bioavailability in existing antiretroviral therapies.